Haan and colleagues 1 reported a cross-sectional study on the association between uterine fibroids (UF), hypertension, and asymptomatic organ damage. The major question that arises from this study is, Are UF directly linked to hypertension or is hypertension or some related factors involved in the onset or growth of fibroids?
| INTRODUC TI ON
Haan and colleagues 1 reported a cross-sectional study on the association between uterine fibroids (UF), hypertension, and asymptomatic organ damage. The major question that arises from this study is, Are UF directly linked to hypertension or is hypertension or some related factors involved in the onset or growth of fibroids?
Uterine fibroids are benign tumors of the muscle layer of uterus, affecting about 70% of women by age 50 years, even if only 30% of patients are symptomatic and request treatment. 2 UF can be considered a fibrotic disease starting with an invasion of inflammatory cells at the level of the uterus or alternatively by an increase of resident fibrotic cells. 3 It is well known that the female genital tract is less reactive to inflammation and autoimmunity and this pattern allows spermatozoa to exert their reproductive function still maintaining a full protection against microbial invasion.
The pathogenesis of UF involves a genetic predisposition influenced by the effect of several hormones. Both estradiol and progesterone have a role in the normal development of uterine mucosa and in the preparation of the uterus for pregnancy, but their involvement in hypertension risk is not proven. High amounts of estrogens can produce hypertension, as reported for some contraceptives, but these associations do not induce UF development or increase their volume. The hypertension caused by contraceptives has been related to the increase of angiotensinogen and activation of reninangiotensin-aldosterone system (RAAS) or to a direct effect of estradiol at the kidney level producing sodium retention.
A previous study has shown that the risk of hypertension in UF is not influenced by hysterectomy with ovarian conservation and on the contrary hysterectomy is associated with long-term increase of cardiovascular risk. 4 These studies are consistent with an extra uterine mechanism underlying the association of hypertension and UF.
Progesterone may play an important role in UF development, stimulating cellular proliferation and fibroid growth. 5 Fibroids express elevated levels of both types of progesterone receptors (PR), PRα and PRβ, compared to the surrounding myometrium. 6 These findings suggest a certain role of progesterone and PR in UF pathogenesis but not in hypertension, progesterone being a mineralocorticoid receptor (MR) antagonist.
Uterine fibroid size is significantly reduced in response to the PR antagonist mifepristone (RU486) or to the selective PR modulator ulipristal acetate, which are also effective at controlling uterine bleeding and reducing collagen deposits. 7 Ulipristal does not have antialdosteronic properties like progesterone and for this reason it is effective in ameliorating UF volume, but it is not effective in reducing the cardiovascular risk and hypertension.
| ANG I OTEN S IN II AND ALDOS TERONE COMMITMENT IN UF
A previous study 8 These findings suggest a possible use of MR antagonists for the treatment of UF; however, only a pure MR antagonist such as eplerenone could be considered, because spironolactone is frequently associated with metrorrhagia because of its effect on PR. 11 In the last decades many studies revaluated the role of aldosterone in the pathogenesis of inflammation and atherosclerosis. 12 The increased cardiovascular risk due to aldosterone is evident in We have hypothesized a relationship between inflammation, aldosterone, and somatic mutations. 16 Recurrent somatic mutations have been involved in increased aldosterone production and adrenal cortex cell proliferation. 17 Currently, about 50% of sporadic aldosterone-producing adenoma cases have been associated with some genetic defects. Recently, somatic mutation of MED 12 gene has been reported in UF, confirming a role of inflammation in UF development. 18 It is also interesting to note that UF are associated with other inflammatory diseases, such as obesity, insulin resistance, and polycystic ovary syndrome (PCOS). In particular, UF are very frequent in PCOS, 19 which is often associated with increased aldosterone levels or with higher aldosterone-to-renin ratio compared with normal controls. PCOS is also linked to many aldosterone-related pathological conditions, like hypertension, Hashimoto's thyroiditis, diabetes, obesity, and preeclampsia. 20 Many of these clinical situations are evident after menopause and a precox treatment could reduce the risk of late complications. 21 
| CON CLUS IONS
Excluding hypertension, Haan and associates 1 did not find a correlation between UF and other factors linked to cardiovascular risk, but this finding could be related to the concomitant treatment of hypertension or to the heterogeneity of UF and of patients' age.
Local and general inflammatory status has been associated with UF development. Many other clinical situations are linked to inflammation, for example, PCOS, metabolic syndrome, insulin resistance, obesity, and diabetes. All of these situations can be associated with UF. Therefore, we believe that UF could be associated with future cardiovascular risk like all the other inflammatory-related hormonal situations frequently associated with UF.
The RAAS involvement in inflammation-linked pathological conditions could play a pathogenetic role and should be considered.
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